Experimental Hematology
Volume 36, Issue 12 , Pages 1634-1641 , December 2008

Bioluminescent evaluation of the therapeutic effects of total body irradiation in a murine hematological malignancy model

  • Yusuke Inoue

      Affiliations

    • Department of Radiology, Institute of Medical Science, University of Tokyo, Tokyo, Japan
    • Corresponding Author InformationOffprint requests to: Yusuke Inoue, MD, Department of Radiology, Institute of Medical Science, University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan
    • ,
  • Kiyoko Izawa

      Affiliations

    • Division of Molecular Therapy, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan
    • ,
  • Shigeru Kiryu

      Affiliations

    • Department of Radiology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
    • ,
  • Seiichiro Kobayashi

      Affiliations

    • Division of Molecular Therapy, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan
    • ,
  • Arinobu Tojo

      Affiliations

    • Division of Molecular Therapy, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan
    • ,
  • Kuni Ohtomo

      Affiliations

    • Department of Radiology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan

Received 28 June 2008 ,Revised 18 August 2008 ,Accepted 20 August 2008.

References 

  1. Contag CH, Jenkins D, Contag PR, Negrin RS. Use of reporter genes for optical measurements of neoplastic disease in vivo. Neoplasia. 2000;2:41–52
  2. Edinger M, Cao YA, Hornig YS, et al. Advancing animal models of neoplasia through in vivo bioluminescence imaging. Eur J Cancer. 2002;38:2128–2136
  3. Inoue Y, Izawa K, Tojo A, et al. Monitoring of disease progression by bioluminescence imaging and magnetic resonance imaging in an animal model of hematologic malignancy. Exp Hematol. 2007;35:407–415
  4. Edinger M, Cao YA, Verneris MR, Bachmann MH, Contag CH, Negrin RS. Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging. Blood. 2003;101:640–648
  5. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004;305:399–401
  6. Wu KD, Cho YS, Katz J, et al. Investigation of antitumor effects of synthetic epothilone analogs in human myeloma models in vitro and in vivo. Proc Natl Acad Sci U S A. 2005;102:10640–10645
  7. Armstrong SA, Kung AL, Mabon ME, et al. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell. 2003;3:173–183
  8. Xin X, Abrams TJ, Hollenbach PW, et al. CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice. Clin Cancer Res. 2006;12:4908–4915
  9. Paroo Z, Bollinger RA, Braasch DA, et al. Validating bioluminescence imaging as a high-throughput, quantitative modality for assessing tumor burden. Mol Imaging. 2004;3:117–124
  10. Nogawa M, Yuasa T, Kimura S, et al. Monitoring luciferase-labeled cancer cell growth and metastasis in different in vivo models. Cancer Lett. 2005;217:243–253
  11. Szentirmai O, Baker CH, Lin N, et al. Noninvasive bioluminescence imaging of luciferase expressing intracranial U87 xenografts: correlation with magnetic resonance imaging determined tumor volume and longitudinal use in assessing tumor growth and antiangiogenic treatment effect. Neurosurgery. 2006;58:365–372
  12. Smakman N, Martens A, Kranenburg O, Borel Rinkes IH. Validation of bioluminescence imaging of colorectal liver metastases in the mouse. J Surg Res. 2004;122:225–230
  13. Mandl SJ, Mari C, Edinger M, et al. Multi-modality imaging identifies key times for annexin V imaging as an early predictor of therapeutic outcome. Mol Imaging. 2004;3:1–8
  14. Jenkins DE, Oei Y, Hornig YS, et al. Bioluminescent imaging (BLI) to improve and refine traditional murine models of tumor growth and metastasis. Clin Exp Metastasis. 2003;20:733–744
  15. Scatena CD, Hepner MA, Oei YA, et al. Imaging of bioluminescent LNCaP-luc-M6 tumors: a new animal model for the study of metastatic human prostate cancer. Prostate. 2004;15(59):292–303
  16. Zeamari S, Rumping G, Floot B, Lyons S, Stewart FA. In vivo bioluminescence imaging of locally disseminated colon carcinoma in rats. Br J Cancer. 2004;90:1259–1264
  17. Nyati MK, Symon Z, Kievit E, et al. The potential of 5-fluorocytosine/cytosine deaminase enzyme prodrug gene therapy in an intrahepatic colon cancer model. Gene Ther. 2002;9:844–849
  18. Rehemtulla A, Stegman LD, Cardozo SJ, et al. Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging. Neoplasia. 2000;2:491–495
  19. Wissink EH, Verbrugge I, Vink SR, et al. TRAIL enhances efficacy of radiotherapy in a p53 mutant, Bcl-2 overexpressing lymphoid malignancy. Radiother Oncol. 2006;80:214–222
  20. Lee CK. Evolving role of radiation therapy for hematologic malignancies. Hematol Oncol Clin North Am. 2006;20:471–503
  21. Kal HB, Loes van Kempen-Harteveld M, Heijenbrok-Kal MH, Struikmans H. Biologically effective dose in total-body irradiation and hematopoietic stem cell transplantation. Strahlenther Onkol. 2006;182:672–679
  22. Gabriel DA, Shea TC, Serody JS, et al. Cytoprotection by amifostine during autologous stem cell transplantation for advanced refractory hematologic malignancies. Biol Blood Marrow Transplant. 2005;11:1022–1030
  23. Nieder C, Licht T, Andratschke N, Peschel C, Molls M. Influence of differing radiotherapy strategies on treatment results in diffuse large-cell lymphoma: a review. Cancer Treat Rev. 2003;29:11–19
  24. Gustavsson A, Osterman B, Cavallin-Ståhl E. A systematic overview of radiation therapy effects in non-Hodgkin's lymphoma. Acta Oncol. 2003;42:605–619
  25. Inoue Y, Tojo A, Sekine R, et al. In vitro validation of bioluminescent monitoring of disease progression and therapeutic response in leukaemia model animals. Eur J Nucl Med Mol Imaging. 2006;33:557–565
  26. Copelan EA, McGuire EA. The biology and treatment of acute lymphoblastic leukemia in adults. Blood. 1995;85:1151–1168
  27. Li S, Ilaria RL, Million RP, Daley GQ, Van Etten RA. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med. 1999;189:1399–1412
  28. Baba S, Cho SY, Ye Z, Cheng L, Engles JM, Wahl RL. How reproducible is bioluminescent imaging of tumor cell growth? Single time point versus the dynamic measurement approach. Mol Imaging. 2007;6:315–322
  29. Lin CS, Goldthwait DA, Samols D. Induction of transcription from the long terminal repeat of Moloney murine sarcoma provirus by UV-irradiation, x-irradiation, and phorbol ester. Proc Natl Acad Sci U S A. 1990;87:36–40
  30. Cheng X, Iliakis G. Effect of ionizing radiation on the expression of chloramphenicol acetyltransferase gene under the control of commonly used constitutive or inducible promoters. Int J Radiat Biol. 1995;67:261–267
  31. Faure E, Cavard C, Zider A, Guillet JP, Resbeut M, Champion S. X irradiation-induced transcription from the HIV type 1 long terminal repeat. AIDS Res Hum Retroviruses. 1995;11:41–43
  32. Dent P, Yacoub A, Contessa J. Stress and radiation-induced activation of multiple intracellular signaling pathways. Radiat Res. 2003;159:283–300
  33. Chastel C, Jiricny J, Jaussi R. Activation of stress-responsive promoters by ionizing radiation for deployment in targeted gene therapy. DNA Repair. 2004;3:201–215
  34. Kim S, Lee K, Kim MD, et al. Factors affecting the performance of different long terminal repeats in the retroviral vector. Biochem Biophys Res Commun. 2006;343:1017–1022
  35. LoSardo JE, Cupelli LA, Short MK, Berman JW, Lenz J. Differences in activities of murine retroviral long terminal repeats in cytotoxic T lymphocytes and T-lymphoma cells. J Virol. 1989;63:1087–1094
  36. Svensson RU, Barnes JM, Rokhlin OW. Chemotherapeutic agents up-regulate the cytomegalovirus promoter: implications for bioluminescence imaging of tumor response to therapy. Cancer Res. 2007;67:10445–10454
  37. Kim KI, Kang JH, Chung JK, et al. Doxorubicin enhances the expression of transgene under control of the CMV promoter in anaplastic thyroid carcinoma cells. J Nucl Med. 2007;48:1553–1561

PII: S0301-472X(08)00391-3

doi: 10.1016/j.exphem.2008.08.004

Experimental Hematology
Volume 36, Issue 12 , Pages 1634-1641 , December 2008

Article Tools

* Image Usage & Resolution